2- imino- 5- ((5- (2- nitrophenyl)furan- 2- yl)methylene)thiazolidin- 4- one
improves muscle function by restoring dystrophin expression; structure in first source
Also Known As:
RTC13; read-through compound 13
Networked: 3
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
1. | Barquinero, Jordi:
2 articles
(01/2020 - 01/2020)
|
2. | Andreu, Antoni L:
1 article
(01/2020)
|
3. | Arenas, Joaquin:
1 article
(01/2020)
|
4. | Brull, Astrid:
1 article
(01/2020)
|
5. | Cortina, Vicente:
1 article
(01/2020)
|
6. | Krag, Thomas O:
1 article
(01/2020)
|
7. | Lucia, Alejandro:
1 article
(01/2020)
|
8. | Martorell, Lluis:
1 article
(01/2020)
|
9. | Martín, Miguel Angel:
1 article
(01/2020)
|
10. | Moya, Laura:
1 article
(01/2020)
|
Related Diseases
1. | Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker)
|
2. | Hemophilia A (Haemophilia)
01/01/2020
- " To this end, primary fibroblasts from three patients with hemophilia A caused by nonsense mutations (p.W1586X, p.Q1636X and p.R1960X) and Chinese hamster ovary (CHO) cells transfected with 12 different plasmids encoding mutated F8 (p.Q462X, p.Q1705X, p.Q1764X, p.W274X, p.W1726X, p.W2015X, p.W2131X, p.R1715X, p.R1822X, p.R1960X, p.R2071X and p.R2228X) were treated with gentamicin, geneticin, PTC124, RTC13 or RTC14. "
|
3. | Glycogen Storage Disease Type V (McArdle's Disease)
|
|
Related Drugs and Biologics